Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29685881.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0463.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor-positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. <i>Clin Cancer Res; 24(13); 2981-3. ©2018 AACR</i><i>See related article by Shah et al., p. 2999</i>.
Medical subject headings
- Breast Neoplasms